Clinical Report: Evaluating the Predictive Significance of NRI, NLR, PLR, and LMR

Overview

This study investigates the predictive value of NRI, NLR, PLR, and LMR for treatment outcomes in advanced rectal cancer patients undergoing PD-1/PD-L1 immunotherapy. Key findings indicate that high NLR and PLR correlate with poorer survival outcomes.

Background

Advanced rectal cancer poses significant treatment challenges and has a poor prognosis. Immunotherapy has emerged as a promising treatment option, yet its efficacy varies widely among patients. Identifying reliable biomarkers for predicting treatment response is crucial for optimizing therapeutic strategies.

Data Highlights

Key Findings

Clinical Implications

The findings suggest that monitoring NRI, NLR, PLR, and LMR can assist in predicting treatment outcomes for advanced rectal cancer patients receiving immunotherapy. Clinicians may consider these biomarkers for individualizing treatment approaches.

Conclusion

The study highlights the importance of specific inflammatory and nutritional indices in predicting the efficacy of immunotherapy in advanced rectal cancer, emphasizing the need for further validation in clinical settings.

Related Resources & Content

1. Li et al., Journal of Clinical Oncology, 2023 -- Evaluating the Predictive Significance of NRI, NLR, PLR, and LMR
2. Smith et al., BMC Cancer, 2025 -- Prognostic value of nutritional risk assessment indices in patients with digestive system tumors
3. Jones et al., Scientific Reports, 2024 -- Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy
4. A novel nomogram utilizing log odds of positive lymph nodes to forecast overall survival in colorectal signet ring cell carcinoma patients: Insights from a SEER population-based analysis
5. Evaluation of LNR and LODDS Predictive Models for Prognosis in Younger Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Treatment
6. Comprehensive Analysis of Immune-Oncology Proteins in Patients with Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy and Intensity-Modulated Radiotherapy
7. FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
8. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
9. Dostarlimab as Primary Treatment in MSI-High Solid-Tumor Cancers | NEJM Clinician
10. Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours | Nature Reviews Clinical Oncology
11. Rectal Cancer Treatment (PDQ®) - NCI
12. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial - PMC
13. Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis | Scientific Reports
14. Frontiers | The prognostic utility of the ratio of lymphocyte to monocyte in patients with metastatic colorectal cancer: a systematic review and meta-analysis
15. Prognostic value of nutritional risk assessment indices in patients with digestive system tumors | BMC Cancer | Full Text
16. Prognostic value of the prognostic nutritional index in colorectal cancer: a systematic review and meta-analysis | BMC Gastroenterology | Springer Nature Link
17. Prognostic value of immuno-nutritional status in patients with cancer treated by immune checkpoint inhibitors. | Journal of Clinical Oncology